仙乐健康(300791)：中国业务改善 海外业务提速

Core Viewpoint - The company reported a significant increase in revenue and net profit for Q3 2025, with year-on-year growth of 18.11% and 16.20% respectively, slightly exceeding expectations [1][4] Revenue and Profit Performance - For Q3 2025, the company achieved revenue of 1.25 billion and net profit of 99 million, reflecting year-on-year growth of 18.11% and 16.20% [1] - For the first three quarters of 2025, the company reported revenue of 3.29 billion, net profit of 260 million, and adjusted net profit of 244 million, with year-on-year growth of 7.96%, 8.53%, and 3.42% respectively [1] Regional Performance - In the China region, Q3 revenue grew by over 20% year-on-year, with overall orders increasing by over 25%, driven by new consumption markets [2] - The Americas region saw export revenue grow by over 20% year-on-year for the first three quarters, with Q3 growth influenced by order confirmation timing [2] - The Europe region experienced over 35% year-on-year revenue growth in Q3, benefiting from partnerships with well-known health food retailers and successful project deliveries [2] Profitability Metrics - The gross margin for Q3 was 30.76%, an increase of 1.12 percentage points year-on-year, attributed to optimized pricing strategies and cost reduction efforts [2] - The selling expense ratio was 7.72%, up by 0.45 percentage points year-on-year, due to increased sales team and marketing expenses [2] - The net profit margin was 7.93%, slightly down by 0.13 percentage points year-on-year, impacted by rising expense ratios [2] Future Outlook - The company anticipates continued growth in the China region, while the Americas may experience fluctuations due to tariff uncertainties [3] - The European market is expected to maintain strong growth, with overall revenue projected to continue increasing in Q4 [3] - The potential divestiture of the BF personal care business is expected to enhance profit capacity in the coming years [3] Investment Recommendation - The company maintains a "strong buy" rating, supported by improved performance in China and accelerating overseas business [4] - EPS estimates for 2025 and 2026 are projected at 1.17 and 1.33 respectively, with a valuation of 20 times for 2025 [4]